Diabetic Nephropathy, also referred to as Diabetic Kidney Disease, is a progressive kidney condition that damages the capillaries in the kidneys’ glomeruli. It is a common complication of diabetes and one of the leading causes of chronic kidney disease in the western world.
This ailment is characterized by progressive decline in the glomerular filtration rate, elevated arterial blood pressure, and persistent albuminuria. Early treatment is crucial to preventing or delaying the onset of diabetic nephropathy.
The global diabetic nephropathy market is projected to grow at a CAGR of 6% from 2013 to 2018 (forecast period). This is credited to rising incidences of obesity and diabetes across the globe.
Reputed industry players are making huge investments in the research & development of drugs for treating diabetic nephropathy. Moreover, awareness of patients regarding diabetes and kidney-related problems is also on the rise.
These factors will have a favorable impact on market growth. However, stringent regulatory procedures, a time-consuming drug-approval process, and poor therapeutic management of diabetic nephropathy may restrict industry expansion.
Controlling blood pressure and blood glucose levels limits kidney damage. There are various treatment options for diabetic nephropathy. Disease modifying therapies is the largest and most popular method of treatment.
Chief sub-segments of disease modifying therapies encompass diuretics, antioxidant inflammation modulator, rennin inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, monocyte chemo attractants proteins inhibitor, angiotensin-converting enzyme (ACE) inhibitors, and connective tissue growth factor inhibitors.
ACE inhibitors are anticipated to grow at the fastest rate over the forecast period.
North America, Europe, Asia Pacific, and RoW (Rest of the World) are the main geographical markets. Asia Pacific is projected to witness lucrative growth owing to rising incidences of diabetes mellitus amongst its populace.
India and China are estimated to account for a majority of the total diabetics in the coming years. India has been declared the ‘Diabetes Capital’ of the world.
Free Sample Request:
http://www.radiantinsights.com/research/global-diabetic-nephropathy-market-2014-2018/request-sample
North America is another key regional market. Various governments in this region are spreading awareness of diabetes and related kidney disorders. The diabetic nephropathy industry in Europe will benefit from rising expenditure on treatment of diabetes.
Key players in the global diabetic nephropathy market are Novartis International AG, Sanofi S.A., Abbott Laboratories, Merck & Co. Inc., and Pfizer Inc.
This ailment is characterized by progressive decline in the glomerular filtration rate, elevated arterial blood pressure, and persistent albuminuria. Early treatment is crucial to preventing or delaying the onset of diabetic nephropathy.
The global diabetic nephropathy market is projected to grow at a CAGR of 6% from 2013 to 2018 (forecast period). This is credited to rising incidences of obesity and diabetes across the globe.
Reputed industry players are making huge investments in the research & development of drugs for treating diabetic nephropathy. Moreover, awareness of patients regarding diabetes and kidney-related problems is also on the rise.
These factors will have a favorable impact on market growth. However, stringent regulatory procedures, a time-consuming drug-approval process, and poor therapeutic management of diabetic nephropathy may restrict industry expansion.
Controlling blood pressure and blood glucose levels limits kidney damage. There are various treatment options for diabetic nephropathy. Disease modifying therapies is the largest and most popular method of treatment.
Chief sub-segments of disease modifying therapies encompass diuretics, antioxidant inflammation modulator, rennin inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, monocyte chemo attractants proteins inhibitor, angiotensin-converting enzyme (ACE) inhibitors, and connective tissue growth factor inhibitors.
ACE inhibitors are anticipated to grow at the fastest rate over the forecast period.
North America, Europe, Asia Pacific, and RoW (Rest of the World) are the main geographical markets. Asia Pacific is projected to witness lucrative growth owing to rising incidences of diabetes mellitus amongst its populace.
India and China are estimated to account for a majority of the total diabetics in the coming years. India has been declared the ‘Diabetes Capital’ of the world.
Free Sample Request:
http://www.radiantinsights.com/research/global-diabetic-nephropathy-market-2014-2018/request-sample
North America is another key regional market. Various governments in this region are spreading awareness of diabetes and related kidney disorders. The diabetic nephropathy industry in Europe will benefit from rising expenditure on treatment of diabetes.
Key players in the global diabetic nephropathy market are Novartis International AG, Sanofi S.A., Abbott Laboratories, Merck & Co. Inc., and Pfizer Inc.
No comments:
Post a Comment